Search

Your search keyword '"Stöver H"' showing total 202 results
Start Over Author "Stöver H"
202 results on '"Stöver H"'

28. Synthetic Polyampholytes as Macromolecular Cryoprotective Agents

Author

Zhao, J., Johnson, M. A., Fisher, R., Burke, N. A. D., and Stöver, H. D. H.

Abstract

A series of polyampholytes based on different molar ratios on N,N-dimethylaminopropyl methacrylamide (DMAPMA), acrylic acid (AA), and optionally, N-tert-butylacrylamide (t-BuAAm), were prepared by free radical copolymerization, and tested as DMSO-free cryoprotective agents for 3T3 fibroblast cells by using a standard freeze-rethaw protocol. Polybetaines prepared by reaction of DMAPMA homo and copolymers with 1,3-propane sultone were used as additional controls. Results showed strong effects of copolymer composition, molecular weight, polymer and NaCl concentrations, on post-thaw cell viability. Binary (DMAPMA/AA) copolymers showed best post-thaw cell viability of 70% at a 30/70 mol % ratio of DMAPMA/AA, which increased to 90% upon introduction of 9 mol % t-BuAAm while maintaining the 30/70 mol % cation/anion ratio. The use of acrylamide linkages in DMAPMA ensures absence of hydrolytic loss of cationic side chains. These polyampholytes were found to decrease ice crystal size and to form a polymer-rich, ice-free layer around cells, reducing damage from intercellular ice crystals during both freezing and thawing steps. These polyampholytes also dehydrate cells during freezing, which helps protect cells from intracellular ice damage. While cell viability immediately after thawing was high, subsequent culturing revealed poor attachment and long-term viability, which is attributed to residual cell damage from intracellular ice formation. Addition of 2 wt % DMSO or 1% BSA to the polymer-based freeze medium was found to mitigate this damage and result in post-thaw viabilities matching those achieved with 10 wt % DMSO.

Published
2019
Full Text
View/download PDF

34. Mental health in prisons

Author

Blaauw, E, Marle, Hjalmar, Moller, M.L., Stöver, H., Jürgens, R., Gatherer, A., Nikogosian, H., Criminal Law, and Psychiatry

Subjects
SDG 3 - Good Health and Well-being
Published
2007

37. Recommendations for the management of hepatitis C virus infection among people who inject drugs

Author

Robaeys, G, Grebely, J, Mauss, S, Bruggmann, P, Moussalli, J, De Gottardi, A, Swan, T, Arain, A, Kautz, A, Stöver, H, Wedemeyer, H, Schaefer, M, Taylor, L, Backmund, M, Dalgard, O, Prins, M, Dore, GJ, Robaeys, G, Grebely, J, Mauss, S, Bruggmann, P, Moussalli, J, De Gottardi, A, Swan, T, Arain, A, Kautz, A, Stöver, H, Wedemeyer, H, Schaefer, M, Taylor, L, Backmund, M, Dalgard, O, Prins, M, and Dore, GJ

Abstract

In the developed world, the majority of new and existing hepatitis C virus (HCV) infections occur among people who inject drugs (PWID). The burden of HCV-related liver disease in this group is increasing, but treatment uptake among PWID remains low. Among PWID, there are a number of barriers to care that should be considered and systematically addressed, but these barriers should not exclude PWID from HCV treatment. Furthermore, it has been clearly demonstrated that HCV treatment is safe and effective across a broad range of multidisciplinary healthcare settings. Given the burden of HCV-related disease among PWID, strategies to enhance HCV assessment and treatment in this group are urgently needed. These recommendations demonstrate that treatment among PWID is feasible and provides a framework for HCV assessment, management, and treatment. Further research is needed to evaluate strategies to enhance assessment, adherence, and SVR among PWID, particularly as new treatments for HCV infection become available. © 2013 The Author 2013.

Published
2013

39. Substitution treatment and HCV/HIV-infection in a sample of 31 German prisons for sentenced inmates.

Author

SCHULTE, B., STÖVER, H., THANE, K., SCHREITER, C., GANSEFORT, D., REIMER, J., and Stöver, H

Subjects
*HEPATITIS C vaccines, *AIDS vaccines, *DRUG abuse, *PRISONERS' health, *DISEASE prevalence, *THERAPEUTICS
Abstract

Injection drug use (IDU) and IDU-related infectious diseases such as hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections are highly prevalent among prisoners worldwide. However, little is known about the prevalence of IDUs, HCV/HIV and the availability of respective treatment options in German prisons. Data provided by prison physicians of 31 prisons, representing 14,537 inmates, were included in this analysis. The proportion of IDUs among all prisoners was 21.9%. Substitution treatment was available in three out of four prisons (74.2%). Overall, 1137 substitution treatments were provided annually with a wide range of treatment aims. The prevalence rate was 14.3% for HCV and 1.2% for HIV. Around 5.5% of all HCV-infected prisoners were in antiviral treatment annually, 86.5% of all HIV-positive inmates in antiretroviral HIV-treatment. Generally, substitution treatment, and HCV and HIV testing and treatment are available. However, due to abstinence-orientated treatment aims, substitution treatment is rarely available as maintenance treatment, and HCV/HIV-treatment is mainly provided for patients with an existing treatment before imprisonment. The inconsistent data quality necessitates changes in prison-related policy to improve surveillance and to generate aggregated data in German prisons. The selection process in this analysis might lead to overestimating the provision of substitution and antiviral HCV-treatment. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results